The facility is a key component of Moderna's strategic investment into Australia, complemented by the opening of its Regional Research Centre for Respiratory Medicines and Tropical Disease and Moderna's Headquarters for Australia, New Zealand, South. Moderna has officially launched its new vaccine manufacturing facility at Monash University's Clayton campus in southeast Melbourne, marking a significant achievement in advancing mRNA vaccine accessibility and promoting medical research and development in Australia. The Monash Technology Precinct.
We are proud to celebrate the opening of Australia's first large-scale mRNA manufacturing facility, the Moderna Technology Centre - Melbourne (MTC-M), at Monash University's Technology Precinct in Clayton, Victoria. The 10,000-square-meter facility is the first of its kind in the Southern Hemisphere and has the capacity to produce up to 100 million doses annually, supplying essential. Story Continues "Moderna opens Southern Hemisphere's only mRNA manufacturing facility in Victoria" was originally created and published by Investment Monitor, a GlobalData owned brand.
With Moderna and also BioNTech establishing major hubs in the state, Victoria is the only place in the world where both mRNA leaders host research and development (R&D) and manufacturing operations. The facility is the result of a 10-year partnership between the Australian Government, Victorian Government and Moderna. The facility is the result of a 10-year partnership between the Australian Government, the Victorian Government and Moderna to advance Australia's sovereign manufacturing and R&D capability in mRNA medicines and therapeutics.
Moderna's 'too big to fail' mRNA facility opened in Victoria this week with the promise of pumping out up to 100 million doses of mRNA vaccines per year, amid rising vaccine hesitancy and unresolved safety concerns. Based at Monash University's Technology Precinct in southeast Melbourne, the new factory is the result of a 10. Moderna's Headquarters for Australia, New Zealand, South-East Asia, and Oceania in Melbourne, opened in August 2023.
The new headquarters is a significant commitment by Moderna to Victoria's goal of becoming the regional hub for mRNA research, manufacturing, clinical trials, and workforce training. With Moderna and also BioNTech establishing major hubs in the state, Victoria is the only place in the world where both mRNA leaders host research and development (R&D) and manufacturing operations. The facility is the result of a 10-year partnership between the Australian Government, Victorian Government and Moderna to advance Australia's sovereign manufacturing and R&D capability in mRNA.
